Replies to post #217257 on Biotech Values

[DewDiligence]

ADXS—One would think that the stock would, at least, move up a little bit [on news of the MAA submission].

The AXAL MAA is not as big a deal as some message-board posters would have you believe. For the sake of discussion, let’s say ADXS gets EMA conditional approval to treat second-line metastatic cervical cancer… how much do you think cumulative EU sales will be for a product that was conditionally approved based on single-arm data?

A bigger deal for ADXS (IMHO) is the neoantigen-vaccine (ADXS NEO) collaboration with AMGN. I’ll be (pleasantly) surprised if ADXS’ stock has a big run before the NEO program starts dosing patients.